Type 2 diabetes, prediabetes, hypertension, dyslipidemia, sleep apnea, fatty liver disease, cardiovascular disease, and polycystic ovary syndrome all justify semaglutide therapy at a BMI of 27 or lower
It also stimulates insulin production when glucose levels rise, helping to regulate blood sugar
A total of 181,238 AE reports with treatment with GLP-1 RAs were documented in the FAERS database, of which 8,240 were psychiatric AEs
Our team creates personalized therapy plans that address your unique concerns
The selectivity advantage Research published in the European Journal of Endocrinology demonstrated something remarkable about ipamorelin
Currently, GLP-1 agonist molecules are also prescribed off-label for obesity conditions